FORM 7

MONTHLY PROGRESS REPORT – January 2021

Name of Listed Issuer: AMP Alternative Medical Products Inc. (the "Issuer" or "AMP" or "the Company")

Trading Symbols: CSE: XCX; Frankfurt: C4TA; ISIN: CA0318961038

Number of Outstanding Listed Securities: 27,160,611 common shares

Date: February 5th, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

(a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

(a) The term "Issuer" or "AMP" or "the Company" includes the Issuer and any of its subsidiaries.

(a) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

AMP sales in January increased due to more products available for sale to pharmaceutical distributors and pharmacists. The Company continued to expand its sales team.

The Company change its name to AMP Alternative Medical Products Inc. The Company's new ISIN number is CA0318961038, CUSIP number is 031896103 and WKN A2QNUQ. The Frankfurt Stock Exchange symbol has changed to "C4TA", while the Canadian Securities Exchange symbol remains, "XCX".

The Company is investigating whether AMP can list its shares on the electronic trading platform XETRA operated by the Frankfurt Stock Exchange.

2. Provide a general overview and discussion of the activities of management.

Management expanded its specialized medical cannabis sales team with the objective to have sales executives in the five sales regions in Germany by the beginning of Q2, 2021. Refer to Question 10 for further details.

Management worked to qualify new and existing suppliers for the German market, including Eve & Co. Incorporated. Refer to news releases issued on August 11th, 2020.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Beginning in January 2021, AMP sales catalogue includes branded cannabis flower products from Bedrocan from the Netherlands, two branded cannabis extract products from Little Green Pharma from Australia and Aphria Inc. from Canada. Refer to the news release issued on July 6th, 2020, October 22nd, 2020, and January 26th, 2021 respectively.

AMP will launch and begin selling its first AMP-branded product, AMP Classic 18/1, a high-THC cannabis flower which shall be supplied by Schroll Medical of Denmark during Q2, 2021. Refer to the news release dated November 5th, 2020.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

AMP entered into a co-promotion agreement with CC Pharma GmbH, the German and European pharmaceutical distribution company of Aphria Inc. for the sale of Aphria branded products both within the CC Pharma pharmacy networks and to other specialized pharmaceutical distributors and large pharmacies. Refer to the news releases dated on January 26th, 2021.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

   Not applicable.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

   Not applicable.

8. **Describe the acquisition of new customers or loss of customers.**

   Not applicable.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks**.

   Not applicable.

10. **Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.**

    Refer to Question 2. AMP recruited a National Sales leader to spearhead the Company's sales strategy. The Company hired one salesperson in December and recruited an additional salesperson to start in February 2021. AMP is looking forward to recruiting up to three additional sales people before the end of the first quarter of 2021.

11. **Report on any labour disputes and resolutions of those disputes if applicable.**

    Not applicable.

12. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

    Not applicable.

13. **Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

    Not applicable.

14. **Provide details of any securities issued and options or warrants granted.**

    Not applicable.

15. Provide details of any loans to or by Related Persons.

No loans were made to by related parties or persons during this period.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In December 2020, the United Nations (UN) removed cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs, which had been listed alongside opioids such as heroin.

In December 2020, the European Union (EU) removed all uncertainty that cannabis with CBD and THC below 0.2% is not a narcotic, which may result in wellness products being sold without a prescription in Germany and Europe.

In October 2020, the Bundestag, the German federal parliament, rejected a bill to legalize a "strictly controlled" adult-use recreational cannabis market.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak and any related adverse public health developments have adversely affected workforces, economies and financial markets globally, potentially leading to an economic downturn.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: February 5th, 2021

Mr. Nicholas Furber
Name of Director or Senior Officer

/s/ Nicholas Furber
Signature

CFO & Director
Official Capacity

Issuer Details **- Name of Issuer**	**For Month End**	**Date of Report** YY/MM/D
AMP Alternative Medical Products Inc. (Formerly AMP German Cannabis Group Inc.)	January 2021	21/02/05
Issuer Address (Canadian) Suite 224, West 5th Avenue		
City/Province/Postal Code Vancouver, British Columbia, V5Y 1J4 Canada	**Issuer Fax No.** (604) 683 9681	**Issuer Telephone No.** (604) 689 7533
Contact Name Nicholas Furber	**Contact Position** CFO & Director	**Contact Telephone No.** (604) 689 7533
Contact Email Address investor@amp-eu.com	**Web Site Address** http://www.amp-eu.com	